Navigation Links
Shire plc: Results of the Annual General Meeting Held on April 28, 2009
Date:4/28/2009

DUBLIN, April 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

                                        For*      Against  Withheld**
    1.     To receive the
           Company's accounts
           together with the
           director's and
           auditor's reports    385,589,148    2,271,000     26,380
    2.     To approve the
           Remuneration Report  307,647,526   60,796,610 19,442,392
    3.     To elect Dr Barry
           Price as a Director
           of the Company       356,441,471   31,425,618     19,439
    4.     To re-appoint
           Deloitte LLP as
           Auditors of the
           Company              387,555,848      311,630     19,050
    5.     To authorize the
           Audit, Compliance
           and Risk Committee
           to determine the
           remuneration of the
           Auditors             387,180,598      671,746     34,184
    6.     To authorize the
           allotment of shares  332,997,412   54,868,377     20,739
    7.     To authorize the
           disapplication of
           pre-emption rights   387,558,665      297,124     30,739
    8.     To authorize market
           purchases            387,693,316      173,212     20,000

    * These figures include discretionary votes

** A vote "withheld" is not a vote in law and is not counted in the calculation of the votes "for" or "against" a resolution.

Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

Notes to Editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

    For further information please contact:

    Shire plc:

    Tony Guthrie,
    Deputy Company Secretary,
    +44(0)1256-894746

    Investor Relations

    Clea Rosenfeld (Rest of the World)
    +44-1256-894-160

    Eric Rojas (North America)
    +1-617-551-9715

    Media

    Jessica Mann (Rest of the World)
    +44-1256-894-280

    Matthew Cabrey (North America)
    +1-484-595-8248

    Jessica Cotrone (North America)
    +1-617-613-4640



'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
2. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
3. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
4. Publication of Shire plcs Annual Report 2008
5. Shires Project Playground Gives Boost to Philadelphia
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
8. Shire Announces Opening of Office in Japan
9. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
10. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
11. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 per share will ... of record as of the close of business on June ... of the Board of Directors and may be adjusted as ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers ... a new way to treat the disease. Surviving Mesothelioma has just posted an article ... from several Korean institutions based their mesothelioma study on the fact the Manumycin A, ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):